You just read:

Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Mar 26, 2019, 09:53 ET